UCB Biopharma

General Information

UCB is a global biopharmaceutical company, with a focus on neurology and immunology. Our total revenue grew to €4.5 billion in 2017. We are more than 7,500 people in all four corners of the globe, inspired by patients and driven by science.

UCB’s ambition is to transform the lives of people living with severe diseases. We focus on neurology and immunology disorders – putting patients at the center of our world. We are also leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology.

 

Role in AIMS-2-TRIALS

UCB is involved in the Biomarkers of Autism project, specifically on validating biomarkers in adults, adolescents and children, brain activity and behaviours in early life and validating biomarkers in animal and cellular models. UCB is also involved in the European Clinical Research Network.